These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 28720139

  • 1. The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomes.
    De Marco G, Helliwell P, McGonagle D, Emery P, Coates LC, Hensor EMA, Marzo-Ortega H.
    BMC Musculoskelet Disord; 2017 Jul 18; 18(1):303. PubMed ID: 28720139
    [Abstract] [Full Text] [Related]

  • 2. GO-DACT: a phase 3b randomised, double-blind, placebo-controlled trial of GOlimumab plus methotrexate (MTX) versus placebo plus MTX in improving DACTylitis in MTX-naive patients with psoriatic arthritis.
    Vieira-Sousa E, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, Pimenta S, Pimentel-Santos FM, Gomes JL, Aguiar R, Pinto P, Videira T, Catita C, Santos H, Borges J, Sequeira G, Ribeiro C, Teixeira L, Ávila-Ribeiro P, Martins FM, Canhão H, McInnes IB, Ribeiro RM, Fonseca JE.
    Ann Rheum Dis; 2020 Apr 18; 79(4):490-498. PubMed ID: 32193187
    [Abstract] [Full Text] [Related]

  • 3. Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate.
    van Mens LJJ, de Jong HM, Fluri I, Nurmohamed MT, van de Sande MGH, Kok M, van Kuijk AWR, Baeten D.
    Ann Rheum Dis; 2019 May 18; 78(5):610-616. PubMed ID: 30808625
    [Abstract] [Full Text] [Related]

  • 4. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis: protocol of a randomized, placebo-controlled, double-blind clinical trial (COMPLETE-PsA).
    Mulder MLM, Vriezekolk JE, den Broeder N, Mahler EAM, Helliwell PS, van den Hoogen FHJ, den Broeder AA, Wenink MH.
    Trials; 2020 Feb 10; 21(1):155. PubMed ID: 32041657
    [Abstract] [Full Text] [Related]

  • 5. Sustained remission with methotrexate monotherapy after 22-week induction treatment with TNF-alpha inhibitor and methotrexate in early psoriatic arthritis: an open-label extension of a randomized placebo-controlled trial.
    de Jong HMY, van Mens LJJ, Nurmohamed MT, Kok MR, van Kuijk AWR, Baeten DLP, van de Sande MGH.
    Arthritis Res Ther; 2019 Sep 14; 21(1):208. PubMed ID: 31521192
    [Abstract] [Full Text] [Related]

  • 6. Inhibition of radiographic progression across levels of composite index-defined disease activity in patients with active psoriatic arthritis treated with intravenous golimumab: results from a phase-3, double-blind, placebo-controlled trial.
    Mease P, Husni ME, Kafka S, Chakravarty SD, Harrison DD, Lo KH, Xu S, Hsia EC, Kavanaugh A.
    Arthritis Res Ther; 2020 Mar 06; 22(1):43. PubMed ID: 32143685
    [Abstract] [Full Text] [Related]

  • 7. The GO-DACT protocol: a multicentre, randomized, double-blind, parallel-group study to compare the efficacy of golimumab in combination with methotrexate (MTX) versus MTX monotherapy.
    Vieira-Sousa E, Canhão H, Alves P, Rodrigues AM, Teixeira F, Tavares-Costa J, Bernardo A, Pimenta S, Pimentel-Santos F, Gomes JL, Aguiar R, Videira T, Pinto P, Catita C, Santos H, Borges J, Sequeira G, Ribeiro C, Teixeira L, Ávila-Ribeiro P, Martins FM, Ribeiro RM, Fonseca JE.
    Acta Reumatol Port; 2018 Mar 06; 43(2):80-92. PubMed ID: 30091952
    [Abstract] [Full Text] [Related]

  • 8. Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis.
    Coates LC, Merola JF, Mease PJ, Ogdie A, Gladman DD, Strand V, van Mens LJJ, Liu L, Yen PK, Collier DH, Kricorian G, Chung JB, Helliwell PS.
    Rheumatology (Oxford); 2021 Mar 02; 60(3):1137-1147. PubMed ID: 32864685
    [Abstract] [Full Text] [Related]

  • 9. Radiographic Progression Inhibition with Intravenous Golimumab in Psoriatic Arthritis: Week 24 Results of a Phase III, Randomized, Double-blind, Placebo-controlled Trial.
    Kavanaugh A, Husni ME, Harrison DD, Kim L, Lo KH, Noonan L, Hsia EC.
    J Rheumatol; 2019 Jun 02; 46(6):595-602. PubMed ID: 30770519
    [Abstract] [Full Text] [Related]

  • 10. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study).
    Kavanaugh A, McInnes IB, Mease P, Krueger GG, Gladman D, van der Heijde D, Zhou Y, Lu J, Leu JH, Goldstein N, Beutler A.
    Ann Rheum Dis; 2014 Sep 02; 73(9):1689-94. PubMed ID: 24748630
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and survival of golimumab with and without methotrexate in patients with psoriatic arthritis: A retrospective study from daily clinical practice.
    Sharif K, Gendelman O, Langevitz P, Reitblat T, Watad A, Shoenfeld Y, Azuri J, Amital H, Bragazzi NL, Shovman O.
    Best Pract Res Clin Rheumatol; 2018 Oct 02; 32(5):692-700. PubMed ID: 31203927
    [Abstract] [Full Text] [Related]

  • 12. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
    Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A.
    Ann Rheum Dis; 2015 Mar 02; 74(3):538-46. PubMed ID: 24344160
    [Abstract] [Full Text] [Related]

  • 13. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
    Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Zhou Y, Goldstein N, Braun J.
    J Rheumatol; 2016 Dec 02; 43(12):2120-2130. PubMed ID: 27803138
    [Abstract] [Full Text] [Related]

  • 14. Adalimumab added to a treat-to-target strategy with methotrexate and intra-articular triamcinolone in early rheumatoid arthritis increased remission rates, function and quality of life. The OPERA Study: an investigator-initiated, randomised, double-blind, parallel-group, placebo-controlled trial.
    Hørslev-Petersen K, Hetland ML, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Johansen JS, Østergaard M, Stengaard-Pedersen K, OPERA Study-Group.
    Ann Rheum Dis; 2014 Apr 02; 73(4):654-61. PubMed ID: 23434570
    [Abstract] [Full Text] [Related]

  • 15. Intravenous golimumab is effective in patients with active rheumatoid arthritis despite methotrexate therapy with responses as early as week 2: results of the phase 3, randomised, multicentre, double-blind, placebo-controlled GO-FURTHER trial.
    Weinblatt ME, Bingham CO, Mendelsohn AM, Kim L, Mack M, Lu J, Baker D, Westhovens R.
    Ann Rheum Dis; 2013 Mar 02; 72(3):381-9. PubMed ID: 22661646
    [Abstract] [Full Text] [Related]

  • 16. Achieving sustained minimal disease activity with methotrexate in early interleukin 23-driven early psoriatic arthritis.
    den Braanker H, Wervers K, Mus AMC, Bangoer PS, Davelaar N, Luime J, Tchetverikov I, Hazes JMW, Vis M, Lubberts E, Kok MR.
    RMD Open; 2020 Jul 02; 6(2):. PubMed ID: 32669451
    [Abstract] [Full Text] [Related]

  • 17. Comparing methotrexate monotherapy with methotrexate plus leflunomide combination therapy in psoriatic arthritis (COMPLETE-PsA): a double-blind, placebo-controlled, randomised, trial.
    Mulder MLM, Vriezekolk JE, van Hal TW, Nieboer LM, den Broeder N, de Jong EMGJ, den Broeder AA, van den Hoogen FHJ, Helliwell PS, Wenink MH.
    Lancet Rheumatol; 2022 Apr 02; 4(4):e252-e261. PubMed ID: 38288921
    [Abstract] [Full Text] [Related]

  • 18. A randomised, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus ciclosporin in patients with active psoriatic arthritis.
    Fraser AD, van Kuijk AW, Westhovens R, Karim Z, Wakefield R, Gerards AH, Landewé R, Steinfeld SD, Emery P, Dijkmans BA, Veale DJ.
    Ann Rheum Dis; 2005 Jun 02; 64(6):859-64. PubMed ID: 15528283
    [Abstract] [Full Text] [Related]

  • 19. Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
    Detert J, Bastian H, Listing J, Weiß A, Wassenberg S, Liebhaber A, Rockwitz K, Alten R, Krüger K, Rau R, Simon C, Gremmelsbacher E, Braun T, Marsmann B, Höhne-Zimmer V, Egerer K, Buttgereit F, Burmester GR.
    Ann Rheum Dis; 2013 Jun 02; 72(6):844-50. PubMed ID: 22739990
    [Abstract] [Full Text] [Related]

  • 20. Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques.
    Conaghan PG, Østergaard M, Bowes MA, Wu C, Fuerst T, van der Heijde D, Irazoque-Palazuelos F, Soto-Raices O, Hrycaj P, Xie Z, Zhang R, Wyman BT, Bradley JD, Soma K, Wilkinson B.
    Ann Rheum Dis; 2016 Jun 02; 75(6):1024-33. PubMed ID: 27002108
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.